Advanced search
1 file | 1.09 MB Add to list

Cohort profile : the Nordic Antireflux Surgery Cohort (NordASCo)

(2017) BMJ OPEN. 7(6).
Author
Organization
Abstract
Purpose: To describe a newly created all-Nordic cohort of patients with gastro-oesophageal reflux disease (GORD), entitled the Nordic Antireflux Surgery Cohort (NordASCo), which will be used to compare participants having undergone antireflux surgery with those who have not regarding risk of cancers, other diseases and mortality. Participants: Included were individuals with a GORD diagnosis recorded in any of the nationwide patient registries in the Nordic countries (Denmark, Finland, Iceland, Norway and Sweden) in 1964-2014 (with various start and end years in different countries). Data regarding cancer, other diseases and mortality were retrieved from the nationwide registries for cancer, patients and causes of death, respectively. Findings to date: The NordASCo includes 945 153 individuals with a diagnosis of GORD. Of these, 48 433 (5.1%) have undergone primary antireflux surgery. Median age at primary antireflux surgery ranged from 47 to 52 years in the different countries. The coding practices of GORD seem to have differed between the Nordic countries. Future plans: The NordASCo will initially be used to analyse the risk of developing known or potential GORDrelated cancers, that is, tumours of the oesophagus, stomach, larynx, pharynx and lung, and to evaluate the mortality in the short-term and long-term perspectives. Additionally, the cohort will be used to evaluate the risk of non-malignant respiratory conditions that might be caused by aspiration of gastric contents.
Keywords
GASTROESOPHAGEAL-REFLUX DISEASE, CANCER REGISTRY, DATA QUALITY, COMPLETENESS, COMPARABILITY, POPULATION, TIMELINESS, PREVALENCE, VALIDATION, VALIDITY

Downloads

  • Maret-Ouda 2017 cohort profile.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 1.09 MB

Citation

Please use this url to cite or link to this publication:

MLA
Maret-Ouda, John, et al. “Cohort Profile : The Nordic Antireflux Surgery Cohort (NordASCo).” BMJ OPEN, vol. 7, no. 6, 2017.
APA
Maret-Ouda, J., Wahlin, K., Artama, M., Brusselaers, N., Färkkilä, M., Lynge, E., … Lagergren, J. (2017). Cohort profile : the Nordic Antireflux Surgery Cohort (NordASCo). BMJ OPEN, 7(6).
Chicago author-date
Maret-Ouda, John, Karl Wahlin, Miia Artama, Nele Brusselaers, Martti Färkkilä, Elsebeth Lynge, Fredrik Mattsson, et al. 2017. “Cohort Profile : The Nordic Antireflux Surgery Cohort (NordASCo).” BMJ OPEN 7 (6).
Chicago author-date (all authors)
Maret-Ouda, John, Karl Wahlin, Miia Artama, Nele Brusselaers, Martti Färkkilä, Elsebeth Lynge, Fredrik Mattsson, Eero Pukkala, Pål Romundstad, Laufey Tryggvadóttir, My von Euler-Chelpin, and Jesper Lagergren. 2017. “Cohort Profile : The Nordic Antireflux Surgery Cohort (NordASCo).” BMJ OPEN 7 (6).
Vancouver
1.
Maret-Ouda J, Wahlin K, Artama M, Brusselaers N, Färkkilä M, Lynge E, et al. Cohort profile : the Nordic Antireflux Surgery Cohort (NordASCo). BMJ OPEN. 2017;7(6).
IEEE
[1]
J. Maret-Ouda et al., “Cohort profile : the Nordic Antireflux Surgery Cohort (NordASCo),” BMJ OPEN, vol. 7, no. 6, 2017.
@article{8548983,
  abstract     = {Purpose: To describe a newly created all-Nordic cohort of patients with gastro-oesophageal reflux disease (GORD), entitled the Nordic Antireflux Surgery Cohort (NordASCo), which will be used to compare participants having undergone antireflux surgery with those who have not regarding risk of cancers, other diseases and mortality. 
Participants: Included were individuals with a GORD diagnosis recorded in any of the nationwide patient registries in the Nordic countries (Denmark, Finland, Iceland, Norway and Sweden) in 1964-2014 (with various start and end years in different countries). Data regarding cancer, other diseases and mortality were retrieved from the nationwide registries for cancer, patients and causes of death, respectively. 
Findings to date: The NordASCo includes 945 153 individuals with a diagnosis of GORD. Of these, 48 433 (5.1%) have undergone primary antireflux surgery. Median age at primary antireflux surgery ranged from 47 to 52 years in the different countries. The coding practices of GORD seem to have differed between the Nordic countries. 
Future plans: The NordASCo will initially be used to analyse the risk of developing known or potential GORDrelated cancers, that is, tumours of the oesophagus, stomach, larynx, pharynx and lung, and to evaluate the mortality in the short-term and long-term perspectives. Additionally, the cohort will be used to evaluate the risk of non-malignant respiratory conditions that might be caused by aspiration of gastric contents.},
  articleno    = {e016505},
  author       = {Maret-Ouda, John and Wahlin, Karl and Artama, Miia and Brusselaers, Nele and Färkkilä, Martti and Lynge, Elsebeth and Mattsson, Fredrik and Pukkala, Eero and Romundstad, Pål and Tryggvadóttir, Laufey and von Euler-Chelpin, My and Lagergren, Jesper},
  issn         = {2044-6055},
  journal      = {BMJ OPEN},
  keywords     = {GASTROESOPHAGEAL-REFLUX DISEASE,CANCER REGISTRY,DATA QUALITY,COMPLETENESS,COMPARABILITY,POPULATION,TIMELINESS,PREVALENCE,VALIDATION,VALIDITY},
  language     = {eng},
  number       = {6},
  pages        = {8},
  title        = {Cohort profile : the Nordic Antireflux Surgery Cohort (NordASCo)},
  url          = {http://dx.doi.org/10.1136/bmjopen-2017-016505},
  volume       = {7},
  year         = {2017},
}

Altmetric
View in Altmetric
Web of Science
Times cited: